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Birth defects, which are in part caused by exposure to environmen-
tal chemicals and pharmaceutical drugs, affect 1 in every 33 babies
born in the United States each year. The current standard to screen
drugs that affect embryonic development is based on prenatal
animal testing; however, this approach yields low-throughput and
limited mechanistic information regarding the biological pathways
and potential adverse consequences in humans. To develop a screen-
ing platform for molecules that affect human embryonic development
based on endothelial cells (ECs) derived from human pluripotent stem
cells, we differentiated human pluripotent stem cells into embryonic
ECs and induced their maturation under arterial flow conditions. These
cells were then used to screen compounds that specifically affect
embryonic vasculature. Using this platform, we have identified two
compounds that have higher inhibitory effect in embryonic than
postnatal ECs. One of them was fluphenazine (an antipsychotic),
which inhibits calmodulin kinase II. The other compound was
pyrrolopyrimidine (an antiinflammatory agent), which inhibits vascular
endothelial growth factor receptor 2 (VEGFR2), decreases EC viability,
induces an inflammatory response, and disrupts preformed vascular
networks. The vascular effect of the pyrrolopyrimidine was further
validated in prenatal vs. adult mouse ECs and in embryonic and adult
zebrafish. We developed a platform based on human pluripotent stem
cell-derived ECs for drug screening, which may open new avenues of
research for the study and modulation of embryonic vasculature.
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The development of platforms for the rapid profiling of chem-ical/pharmaceutical substances that have an effect on embry-
onic development is of great interest to reduce human embryo
lethality and birth defects (1). In the United States, ∼3% of all
babies born each year have birth defects (https://www.cdc.gov/
ncbddd/birthdefects/data.html). The majority of birth defects were
the result of multiple environmental and/or genetic effects that
acted in concert. Environmental causes included pesticides,
pharmaceuticals, solvents, metals, and air pollutants (2). The
cardiovascular system is the first functional organ to develop in the
mammalian embryo, and thus, the disruption of the vascular sys-
tem is important for the identification of compounds with de-
velopmental toxicity (3, 4). Disruption of vascular development
has been correlated with fetal loss, human malformations, and
cognitive impairment (5, 6). Standard protocols for assessing the
effect of chemicals on vascular development involve testing on
animals. Unfortunately, these tests are low-throughput, expensive,
yield limited mechanistic information, and do not account for
differences between species. Recent approaches combining high-
throughput screening and high-content screening platforms with
computational systems modeling have been used for the identifi-
cation of vascular-disruptive developmental drugs (3, 4); however,
they do not account for differences between species.
Human pluripotent stem cells (hPSCs) represent a potential
source of embryonic endothelial cells (ECs) (7). hPSC-derived
ECs have not been used for the identification of molecules that
disrupt vascular development, in part because it is relatively un-
known whether hPSC-derived ECs exhibit embryonic features,
because a set of markers to distinguish embryonic ECs from
postnatal ECs has to be identified. In addition, it requires the
validation of the hits identified in static screening conditions under
flow conditions to replicate the hemodynamics of blood vessels.
Approaches to mimic the hemodynamic forces experienced by
vessels in vivo require the development of microfluidic platforms.
Recently, researchers have replicated the circular cross-section of
blood vessels in microfluidic devices (8); however, these tools have
not been used in the context of drug screening. Moreover, it re-
quires a final validation of the hits in animal embryos.
Here, we report a platform suitable for the high-throughput
screening of compounds that affect embryonic vascular development.
Significance
It is well recognized that several chemicals and/or drugs are
potentially harmful if used during pregnancy. Unfortunately,
systems capable of predicting which drugs affect embryonic
development rely almost exclusively on prenatal animal test-
ing, with all the associated limitations. Using human pluripo-
tent stem cells, we developed a fully humanized system
capable of predicting which drugs affect, specifically, vascular
embryonic development. The system was used to screen a li-
brary of chemicals (1,280 drugs), and two compounds were
identified as specific inhibitors of human embryonic vascula-
ture. The platform described here is a valid alternative to ani-
mal testing and can be used to screen existing and newly
developed drugs.
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We established the conditions for the differentiation of hPSCs
into embryonic ECs followed by their maturation under flow
conditions for more accurate toxicological assessment. Using a
high-throughput assay, we identified fluphenazine (an antipsy-
chotic) and 7-cyclopentyl-5-(4-phenoxy)phenyl-7H-pyrrolo[2,
3-d]pyrimidin-4-ylamine (7-Cyclo; an antiinflammatory agent) as
compounds that interfere with cell viability and disrupt in vitro
embryonic vascular networks. Our results further show that 7-Cyclo’s
effect is mediated by the inhibition of vascular endothelial growth
factor receptor 2 (VEGFR2) highly expressed in the embryonic
ECs. These findings were validated in vitro, where we demonstrated
that 0.001 μM 7-Cyclo interferes with hPSC-derived EC cord-like
structure in Matrigel and cell viability. Additionally, in vivo, we
showed that 0.1 μM 7-Cyclo specifically blocks the motility and
sprouting of arterial ECs during intersomitic vessel develop-
ment in zebrafish embryos.
Results
Derivation of ECs from hPSCs. To differentiate human embryonic
stem cells (hESCs) into ECs, we used a protocol that combined
VEGF165 (9), thymosin β4 (Tβ4) (10), and TGF-β inhibitor
(SB431542) (11) as inductive agents of EC differentiation (Fig.
1A). We obtained ∼5% CD31+ cells at 18 d of differentiation. To
determine whether CD31+ cells after 18 d of differentiation could
differentiate into ECs, CD31+ cells were isolated by using magnetic
activated cell sorting (MACS) and cultured in EGM-2 medium
supplemented with SB431542. Gene expression analysis in cells
differentiated for three passages (between 18 and 22 d after cell
seeding) indicated that the cells expressed CD34, vascular endo-
thelial cadherin (VECAD), and VEGFR2 at the same or at a higher
level compared with human umbilical vein ECs (HUVECs), albeit
they exhibited a lower expression of VWF and CD31, which may
indicate different levels of maturation (Fig. 1B). Flow cytometry
and immunocytochemistry analyses showed that CD31+ cells cul-
tured for three passages expressed high levels of EC markers (Fig.
1 C and D), but not other mesoderm-derived cell lineages, such as
the smooth muscle cell marker α-SMA (SI Appendix, Fig. S1A).
Similar results were obtained for ECs derived from human induced
pluripotent stem cells (hiPSCs) generated from cord blood (12) (SI
Appendix, Fig. S2). Microarray data from hESC-derived ECs, hu-
man umbilical artery ECs (HUAECs), human arterial ECs (HAECs),
and HUVECs were integrated. Clustering analysis showed that
hESC-derived ECs are more related to an arterial than a ve-
nous gene expression profile (SI Appendix, Fig. S1B). Overall,
our results showed that we obtained a significantly pure EC
population from hPSCs.
Next, we performed gene microarray for hESC-derived ECs,
HUAECs (fetal cells), and HAECs (adult cells) and compared
the global gene expression with data from ECs isolated from
embryonic day 8.5 (E8.5) mouse embryos (13). Interestingly, the
hESC-derived ECs showed a robust clustering to embryonic ECs
(Fig. 1E). We then used k-means clustering to extract the set of
genes enriched in both embryonic and hES-derived ECs (Fig. 1E
and SI Appendix, Table S2). Thirteen genes were selected and
confirmed by quantitative RT-PCR (qRT-PCR) (DLL1, EPHB2,
LYN, TEK, ID1, NRP2, CAST, FLT1, IGF1, DKK3, NIN, LEF1,
and SORBS3; Fig. 1F and SI Appendix, Fig. S1C). ECs isolated
from embryonic mouse aorta at day E12.5 (mAECs E12.5) and
postnatal day 1 (mAECs p1) were used to confirm the embryonic
identity. qRT-PCR results validated the microarray analysis and
further showed that the 13 genes were up-regulated in mAECs
E12.5 compared with mAECs p1 (Fig. 1F and SI Appendix, Fig.
S1C). Together, the results indicated that hESC-derived ECs
have embryonic-like properties.
Next, we asked whether hESC-derived ECs are functional.
hESC-derived ECs are able to take up Dil-labeled acetylated low-
density lipoprotein and formed cord-like structures when cultured
in the basement membrane Matrigel (Fig. 1C). In addition, hESC-
derived ECs responded to the vasoactive agonists, similar to
HUVECs or HUAECs, by increasing the intracellular levels of
Ca2+ (Fig. 1G). hESC-derived ECs did not respond to thrombin as
HUAECs, and they had different response profiles to VEGF165,
prostaglandin H2-analog, and histamine. No similarity was found in
the response profiles of hESC-derived ECs and HUVECs. Fur-
thermore, hESC-derived ECs responded to proinflammatory stim-
uli, such as tumor necrosis factor alpha (TNF-α), by increasing the
expression of ICAM1, CD40, and VCAM1 (Fig. 1H). Together, our
results show that hESC-derived ECs are functional; however, they
show differences in their activity compared with HUAECs and
HUVECs, which is likely due to their embryonic properties.
To induce the maturation of hESC-derived ECs, we cultured the
cells under flow conditions (20 dyne/cm2) for 7 d. Knowledge about
flow conditions during human embryo development is scarce, and
thus we selected arterial flow conditions (14) to culture the hESC-
derived ECs that have a gene expression profile more related to
arterial ECs (SI Appendix, Fig. S1B). Previous studies have shown
that a mechanosensory complex formed by CD31, VECAD, and
VEGFR2 mediates the responsiveness of ECs to flow shear stress
(15). Indeed, the expression of CD31 and VEGFR2 was up-
regulated in flow conditions (SI Appendix, Fig. S1 D and E), as
previously shown in adult ECs (15). The maturation of the hESC-
derived ECs was also evaluated by their capacity to express hep-
aran sulfate proteoglycan (HSPG), a component of the glycocalyx
layer (16) (SI Appendix, Fig. S1F). HSPG is absent in ECs cultured
in static conditions, as shown in previous studies (16). However,
both hESC-derived ECs and control HUAECs cultured under flow
conditions were abundantly decorated with HSPGs. HSPGs are
detected in the apical region of ECs (XZ view) exposed to flow.
These results showed that hESC-derived ECs responded to flow by
producing HSPG, as observed in vivo. Overall, our results indicated
that hESC-derived ECs mature under flow conditions, as shown by
the up-regulation of the mechanosensory complex and their ca-
pacity to express HSPG.
High-Throughput Identification of Compounds That Interfere with hESC-
Derived EC Activity Followed by Hit Validation in Flow Conditions. To
investigate whether hESC-derived ECs cultured under static and
flow (20 dyne/cm2) conditions can respond to compounds that
interfere with EC activity, we cultured cells for 7 d in each con-
dition, after which the culture medium was supplemented or not
with terbinafine (0.1 and 1 μM), an antiangiogenic drug that sup-
presses EC proliferation and activates EC apoptosis (17, 18), for an
additional day. Our results indicated that the hESC-derived ECs
are highly sensitive to terbinafine because the expression of in-
flammation (ICAM-1; E-SELECTIN), oxidative stress sensing
(HO-1), and vasculature modulation (eNOS) genes was up-
regulated in cells cultured in flow conditions with terbinafine (SI
Appendix, Fig. S3). In addition, the expression of dimethylarginine-
dimethyl-amino-hydrolase (DDAH) genes, a family of enzymes that
metabolizes asymmetric dimethylarginine (ADMA) (19), a marker
of EC dysfunction, was significantly down-regulated in hESC-
derived ECs cultured under flow conditions (P < 0.05 or 0.01;
n = 4), but not in static conditions. Furthermore, the secretion of
ADMA and the ratio of the von Willebrand factor propeptide
(vWFpp):von Willebrand factor (vWF) (20), both indicators of EC
activation/injury, were higher in hESC-derived ECs cultured in flow
conditions in the presence of terbinafine than in static conditions.
Overall, these studies demonstrate that hESC-derived ECs can be
used to test inhibitory molecules, and cells cultured under physi-
ologic shear stress have a higher sensitivity to terbinafine than cells
cultured in static conditions.
Having demonstrated the drug sensitivity of hESC-derived ECs,
we next asked whether we could identify compounds that interfered
with embryonic-like ECs using high-throughput screening. Thus, we
exposed hESC-derived ECs in static conditions to a Library of
Pharmacologically Active Compounds (LOPAC) consisting of
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Fig. 1. Differentiation and properties of hESC-derived ECs. (A) Scheme illustrating the differentiation protocol. (B) Gene expression on hESC-derived ECs. hESC-
derived ECs were obtained from CD31+ cells isolated by MACS and differentiated for three passages (∼22 d after cell seeding). Gene expression was evaluated by
qRT-PCR, and the values were normalized by the corresponding gene expression observed in HUVECs, except for OCT-4, which was normalized by the corre-
sponding gene expression in undifferentiated hESCs. Results are mean ± SEM (n = 4). (C) Expression of EC proteins and functionality of hESC-derived ECs. (Scale
bars: 50 μm.) (D) Flow cytometry analysis of hESC-derived ECs. Percentages of positive cells were calculated based on the isotype controls (gray plot) and are shown
in each histogram plot. Results are mean± SEM (n = 3). (E) Hierarchical clustering showing the integration of gene expression data from hESC-derived ECs (in blue)
and mouse embryonic ECs (data from ref. 13). Our results show that hESC-derived ECs cluster with embryonic ECs more than fetal or adult arterial ECs. The
heatmap displays 10 clusters of genes. The one highlighted in green is a cluster of genes enriched in embryonic and hESC-derived ECs (presented in SI Appendix).
Red designates increased expression, and blue designates decreased expression relative to the mean. (F) qRT-PCR analysis for genes more highly expressed in
embryonic ECs than in fetal or adult ECs. hESC-derived ECs at passage 4, HUAECs, embryonic mouse aortic ECs at day 12.5 (mAEC E12.5), and postnatal day 1
(mAEC p1) have been characterized. Gene expression was normalized by the expression of GAPDH. Results are mean ± SEM (n = 4). Statistical analyses were
performed by an unpaired t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (G) Variation of intracellular Ca2+ in FURA-2–loaded cultured hESC-derived
ECs, HUAECs, or HUVECs in response to several agonists. Traces are representative of six independent experiments for each condition. (H) hESC-derived EC ac-
tivation by exposure to TNF-α (10 ng/mL) for 24 h. The shift in each plot indicates the percentage of cells that express a specific marker after exposure to TNF-α,
subtracted by the percentage of cells that express the corresponding marker in the absence of TNF-α. Results are mean ± SEM (n = 4).
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1,280 bioactive compounds, and we assessed cell viability after 4 d
using a PrestoBlue assay (resazurin-based solution that is reduced
by viable cells) (Fig. 2A). The library was screened at a single
concentration (4.5 μM) according to previous studies using ECs
(21–24) and other cells (25, 26), in a volume of 200 μL per well of
EGM-2 medium containing 0.25% DMSO (vol/vol). To identify
compounds that selectively target ECs, we screened the same li-
brary against human anterior cruciate ligament (ACL) cells. These
cells were chosen because they are nonvascular cells isolated from a
poorly vascularized tissue, and thus their survival does not heavily
rely on blood supply (27). Of the 1,280 compounds, 99 compounds
induced differences in cell viability (hESC-derived ECs vs. ACL
cells) of >50% and were considered for further analyses (SI Ap-
pendix, Table S3). To identify compounds that were selective to
embryonic ECs, but not fetal ECs, we screened the library against
HUAECs (Fig. 2A). Six compounds (danazol, chlorpromazine hy-
drochloride, ellipticine, 3′,4′-dichlorobenzamil, fluphenazine dihy-
drochloride, and 7-Cyclo) affected cell viability in both cells by a
difference of 20% (Fig. 2B). The compounds selected from the
primary screen were then tested against hESC-derived ECs and
HUAECs at different concentrations to obtain a dose–response
curve (Fig. 2C and SI Appendix, Fig. S4). Compounds 7-Cyclo and
fluphenazine dihydrochloride were selected for further testing
due to the significant difference in the effects on hESC-derived
ECs vs. HUAECs.
To test the properties of 7-Cyclo and fluphenazine hydrochlo-
ride in the disruption of vascular networks, microvessels of hESC-
derived ECs and HUAECs were formed on top of Matrigel to
have a patent lumen (SI Appendix, Fig. S5) and subsequently ex-
posed to the drug between 3 and 20 h (depending on the assay).
Our results showed that there was a statistically significant re-
duction in the network length and number of sprouts in micro-
vessels formed by hESC-derived ECs after incubation with 1 μM
7-Cyclo, whereas a negligible effect was observed in microvessels
formed by HUAECs (Fig. 3 A and B and SI Appendix, Fig. S6A).
Importantly, the toxicity of 7-Cyclo against hESC-derived ECs was
extensive to 0.001 μM (SI Appendix, Fig. S7A). A similar trend was
observed for cells treated with fluphenazine, although less pro-
nounced than 7-Cyclo (Fig. 3C and SI Appendix, Fig. S6B).
We complemented these results by evaluating cell metabolism
as well as cell viability by annexin V/propidium iodide (PI) staining
in hESC-derived ECs and HUAECs cultured on top of Matrigel.
Our results show that hESC-derived ECs reduce significantly ATP
production and have significant apoptosis/necrosis when cultured
with 7-Cyclo in concentrations up to 0.001 μM for 3 h (Fig. 3 D
and E and SI Appendix, Fig. S7B). This effect was less pronounced
in HUAECs cultured with 7-Cyclo. In addition, the higher toxicity
of 7-Cyclo (1 μM) against human embryonic ECs compared with
fetal ECs was also confirmed in mouse ECs, specifically mAECs
E12.5 against mAECs p1 (SI Appendix, Fig. S8). Moreover, hESC-
derived ECs were more sensitive to the toxicity effects of flu-
phenazine than HUAECs, although the effect in both cells was
relatively lower than that observed for 7-Cyclo (Fig. 3 F and G).
Fluphenazine has been described as an antipsychotic agent that
inhibits calmodulin in ECs and increases intracellular concentra-
tion of Ca2+ (28). The inhibition of calmodulin leads to the in-
hibition of calmodulin kinase II, which, in turn, inhibits the
phosphorylation of extracellular signal-regulated kinase (ERK)
(29) and finally affects cell survival. Our results indicate that
embryonic ECs cultured with fluphenazine showed higher mobi-
lization of intracellular levels of Ca2+ (SI Appendix, Fig. S9), lower
calmodulin kinase II activity, and lower levels of ERK and AKT
phosphorylation than postnatal ECs (SI Appendix, Fig. S10). For
further testing, we selected 7-Cyclo because hESC-derived ECs
were more susceptible to this compound than fluphenazine.
To evaluate the effects of 7-Cyclo in flow conditions, hESC-
derived ECs were cultured in a poly(dimethylsiloxane) (PDMS)
microfluidic system with cylindrical channels for 7 d at 20 dyne/cm2
(Fig. 4A). ECs were able to form a confluent monolayer on the
entire inner surface of the channel after 48 h. At day 7, cells were
exposed to EGM-2 medium supplemented with 1 μM 7-Cyclo
for 24 h, and their gene expression and secretome were analyzed
A B
C
Fig. 2. High-throughput screening (HTS) to identify
compounds that interfere with hESC-derived ECs.
(A) Schematic representation of the HTS assay.
(B) Small molecules identified after the analysis of the
primary screen. The hits have preferential cytotoxicity
against hESC-derived ECs. IC50 values are for hESC-
derived ECs. (C) Dose–response curve for HUAECs
and hESC-derived ECs exposed to 7-Cyclo and flu-
phenazine. Values are normalized against nontreated
cells (control). Results are mean ± SEM (n = 4).
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(Fig. 4B). Our results revealed that hESC-derived ECs showed
significant cell death (SI Appendix, Fig. S11A). In addition, hESC-
derived ECs exposed to 7-Cyclo expressed significantly higher
levels of inflammatory genes, such as ICAM-1, E-SELECTIN,
HO-1, and eNOS (P < 0.0001, n = 4), and expressed lower levels of
DDAH1 and DDAH2 (P < 0.05 or 0.0001, n = 4), which are en-
zymes that metabolize ADMA, compared with cells cultured under
static conditions (Fig. 4C). Interestingly, EC inflammation and
injury occurred upstream of cell apoptosis/necrosis (SI Appendix,
Fig. S11B). In the case of HUAECs cultured under the same
conditions, the effect was less pronounced. No down-regulation of
DDAH-1 and -2 was observed. We complemented these gene
analyses with analyses of ADMA and the ratio of vWFpp:von vWF
secreted by these cells (Fig. 4D). hESC-derived ECs or HUAECs
cultured in static conditions in the presence of the drug demon-
strated similar secretion of ADMA or vWFpp:vWF as control
conditions (i.e., without the drug). Importantly, hESC-derived ECs
cultured under flow conditions in the presence of 7-Cyclo secreted
higher levels of ADMA (2.5-fold) and vWFpp:vWF (1.6-fold) than
without the drug, and significantly higher levels of ADMA were
observed compared with HUAECs. This result was likely due to
differences in the expression profile of 7-Cyclo molecular targets
(i.e., tyrosine kinases; see below) either in static or flow conditions
(SI Appendix, Fig. S12). Overall, our results indicated that hESC-
derived ECs were more sensitive to the effects of 7-Cyclo com-
pared with HUAECs.
To further confirm the effects of 7-Cyclo in the embryonic vas-
culature, we incubated mAECs E12.5 and mAECs p1 with 7-Cyclo
(1 μM) for 24 h under static conditions. Inflammation, oxidative
stress sensing, vascular modulation, and vascular injury-sensing
genes were statistically up-regulated in mAECs E12.5 compared
with cells without treatment (SI Appendix, Fig. S13). In contrast,
7-Cyclo had no effect on mAECs p1. The degree of action of
7-Cyclo in mAECs E12.5 was similar to the effect identified in
hESC-derived ECs (Fig. 4C).
We further validated these findings in vivo using zebrafish
Tg(fli1a:eGFP)y1 embryos (30) by evaluating the effect of 7-Cyclo
on the development of intersegmental blood vessels (ISVs). The
7-Cyclo was added to the water of 22–23 h postfertilization (hpf)
embryos at a concentration of 0, 0.1, 1, and 10 μM for 8 h, and
A
B.1
B.2
C.1
C.2
D E F G
Fig. 3. Effect of 7-Cyclo and fluphenazine in angiogenesis, cell survival, and metabolism. (A) Secondary assays to show the preferential effect of 7-Cyclo in hESC-
derived ECs than HUAECs. (B and C) Quantification of length (B1 and C1) and sprouts (B2 and C2) of cord-like structures in hESC-derived ECs, HUAECs, or HUAECs
overexpressing VEGFR2 cultured on top of Matrigel for 12 h and then exposed for 0, 3, and 20 h to 7-Cyclo (B) or fluphenazine (C). Results are mean ± SEM (n = 4;
two phase-contrast images per well and time). In B and C, statistical analyses between experimental groups and no treatment (0 μM 7-Cyclo) for the same time
were performed by a one-way ANOVA test followed by a Newman–Keuls multiple comparisons test. (D and F) ATP analyses on hESC-derived ECs or HUAECs
cultured on top of Matrigel for 12 h and then exposed for 3 h to 7-Cyclo (D) or fluphenazine (F). Results are mean ± SEM (n = 4). Statistical analyses were
performed by one-way ANOVA test followed by a Newman–Keuls multiple comparisons test. (E and G) Quantification by flow cytometry of cell viability (annexin−/PI−),
necrosis (annexin−/PI+), early (annexin+/PI−), and late (annexin+/PI+) apoptosis by using annexin V/PI staining, in cells cultured on top of Matrigel for 12 h and then
exposed for 3 h to 7-Cyclo (E) or fluphenazine (G). Results are mean ± SEM, n = 4. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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(i) the number of ISVs, (ii) number of ISVs reaching the dorsal
longitudinal anastomotic vessel (DLAV), and (iii) percentage of
caudal plexus sprouts was quantified (Fig. 5 A and B). Our results
show that 7-Cyclo is toxic to zebrafish embryos at a concentration
of 0.1–1 μM. At concentrations of 1 μM, 7-Cyclo blocked the
motility and sprouting behavior of arterial ECs during intersomitic
vessel development in zebrafish embryos. We also evaluated the
effect of 7-Cyclo in adult zebrafish Tg(fli1a:eGFP)y1. Because drug
accessibility and pharmacokinetics is likely different in both models
(31), the concentration and time of exposure of 7-Cyclo will be
different, making a direct comparison difficult. To overcome this
issue, we evaluated the effect of 7-Cyclo on the zebrafish caudal fin
regeneration model (SI Appendix, Fig. S14). In this model, we
could monitor simultaneously the effect of 7-Cyclo in the pre-
formed vasculature (mature ECs) and in the forming vasculature
[immature ECs; more dependent in VEGF signaling than pre-
formed vasculature (31)]. The zebrafish tail fin is very thin and
optically transparent, which facilitates the vascular toxicity moni-
toring. Our results clearly show a more dramatic effect of the drug
on newly formed vessels than on the preexistent vessels in the adult.
Effect of 7-Cyclo in Embryonic ECs. The 7-Cyclo is a cell-permeable
pyrrolopyrimidine that acts as a potent inhibitor of tyrosine ki-
nases (32). To understand the distinct effect of 7-Cyclo in em-
bryonic vs. fetal/adult ECs, we mined the microarray data and
compared the expression levels of different kinases. Of the
38 genes that encode for tyrosine kinases (Fig. 5D and SI Ap-
pendix, Table S4), 13 of the genes (EFS, VEGFR2, LYN, EGFR,
ZAP70, FLT1, FLT4, LTK, MERTK, NRP1, NTRK2, TEK, and
TYRO3) were expressed at higher levels in hESC-derived ECs
compared to HUAECs or HEACs. The expression of EFS,
VEGFR2, LYN, EGFR, ZAP70, NRP1, and TEK was further
confirmed by using qRT-PCR (Fig. 5C).
Next, we evaluated the expression of tyrosine kinase genes on
mAECs E12.5 and p1 to validate the results obtained in hESC-
derived ECs. The same results were observed—that is, tyrosine
kinases were expressed more in embryonic ECs (in human and
mouse) compared with fetal/adult tissues [except for EGFR in
mouse (Egfr)]. The kinase activity of hESC-derived ECs and
HUAECs was assessed by using luminescence (signal is inversely
correlated with the level of kinase activity) in the absence or
presence of compound 7-Cyclo (Fig. 5E). After 24 h of in-
cubation with 7-Cyclo (0.1 or 1 μM), the kinase activity of hESC-
derived ECs decreased significantly from time 0 (P < 0.01),
whereas no significant decrease was observed in HUAECs.
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Fig. 4. Effect of 7-Cyclo in flow conditions. (A) Macroscopic view of the PDMS microfluidic system (the microchannels have a diameter of 900 μm and an average
length of 0.5 cm) and fluorescent images of microchannel cross-sections showing that ECs can grow in the inner surface of the microfluidic channel after 48 h and
be stable for at least 7 d at 20 dyne/cm2. (Scale bars: 50 μm.) (B) Schematic representation of the experiments performed to evaluate the effect of 7-Cyclo in ECs
cultured under flow or static conditions. (C) Expression of genes involved in inflammation (ICAM-1; E-SELECTIN), oxidative stress sensing (HO-1), vascular mod-
ulation (eNOS), and vascular injury sensing (DDAH1 and DDAH2) in hESC-derived ECs and HUAECs after 24 h of incubation with 0 or 1 μM 7-Cyclo. Results are
mean ± SEM (n = 4). Statistical analyses between groups at static or flow conditions were performed by an unpaired t test. (D) Quantification of ADMA and
vWFpp:vWF by ELISA in hESC-derived ECs and HUAECs after 24 h incubation with 1 μM7-Cyclo. Results are mean± SEM (n = 6). Statistical analyses were performed
by one-way ANOVA test followed by a Newman–Keuls multiple comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Together, our results indicate that 7-Cyclo affects hESC-derived
ECs, which likely inhibits tyrosine kinases that are highly
expressed in the embryonic state.
VEGFR2 is an important target of 7-Cyclo because the IC50 of
the drug for this tyrosine kinase is 1.57 μM (33). Therefore, we
evaluated the effect of the drug in the phosphorylation of
VEGFR2. The phosphorylation decreased significantly in hESC-
derived cells, but not in HUAECs (Fig. 6A). However, if we
overexpressed VEGFR2 in HUAECs (SI Appendix, Fig. S15), we
had a significant decrease in VEGFR2 phosphorylation (Fig. 6A),
as well as in the length and sprouts of cord-like vessels formed on
Matrigel (Fig. 3B). Like in the human system, in the mouse system
the phosphorylation decreased in mAEC E12.5, but not in
mAECs p1, indicating that embryonic ECs are more sensitive to
7-Cyclo than postnatal ECs (Fig. 6A). Our results further showed
that the increased sensitivity of embryonic ECs to 7-Cyclo is likely
due to their higher expression of VEGFR2 (hESC-ECs: 76.5 ±
2.9; mAEC E12.5: 67.3 ± 3.1) compared with postnatal ECs
(HUAECs: 70.4 ± 2.1; mAECs p1: 49.6 ± 2.6) (Fig. 6B). The
increased sensitivity of embryonic ECs to 7-Cyclo is not due to
A B
C
D E
Fig. 5. Effect of 7-Cyclo in zebrafish embryos and molecular targets. (A) Effect of 7-Cyclo on zebrafish embryos. Tg(fli1a:EGFP)y1 Danio rerio were incubated
for 8 h at the concentrations shown (A1–A4) and starting at 22–23 hpf. Insets show the effect of 7-Cyclo in ISVs reaching the DLAV (arrowheads). (Scale bars:
100 μm.) (B) Embryos were scored for the number of ISVs along the anterior–posterior axis, the number of ISV’s that reach the DLAV, and for the presence or
absence of sprouts at the caudal plexus. Ten or more embryos were tested per experimental group per independent experiment (total of three independent
experiments). The data shown are representative of one of three independent experiments. Statistical analyses were performed by one-way ANOVA test
followed by a Bonferroni multiple comparisons test. (C) Expression of tyrosine kinases by qRT-PCR. Gene expression was normalized by the expression of
GAPDH. Results are mean ± SEM (n = 4). Statistical analyses were performed by a Mann–Whitney test. (D) Microarray analysis showing the expression of
tyrosine kinases in hESC-derived ECs, HUAECs, and HAECs. The list of genes is linked to the heatmap. Some of the tyrosine kinases are more highly expressed in
hESC-derived ECs than in HUAECs or HAECs (displayed in the zoom of the microarray). (E) Kinase activity on hESC-derived ECs and HUAECs after incubation
with variable concentrations of 7-Cyclo. Luminescence is inversely related to kinase activity. Results are mean ± SEM (n = 6). Statistical analyses were performed by
one-way ANOVA test followed by a Newman–Keuls multiple comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001. ns, not significant.
E3028 | www.pnas.org/cgi/doi/10.1073/pnas.1617451114 Vazão et al.
changes in the level of VEGF expression after drug exposure (SI
Appendix, Fig. S16).
Downstream effectors of VEGFR2 are ERK and AKT sig-
naling pathways (34). Phosphorylation of ERK activates cell
proliferation, while phosphorylation of AKT activates cell pro-
liferation, migration, and survival (34, 35). Like ZM323881, a
highly selective inhibitor of VEGFR2 (34), 7-Cyclo reduced
significantly the phosphorylation of both AKT and ERK in
hESC-ECs (Fig. 6 C and D). This effect was significantly lower in
HUAECs. To determine whether the inhibition of AKT and
ERK was synchronized with VEGFR2 inhibition, we performed
dose-effect analyses and calculated the correlation between the
A B
C D E
F
Fig. 6. Effect of 7-Cyclo in VEGFR2. (A) Phosphorylation of VEGR2 in human and mouse embryonic and postnatal cells treated with 0 or 0.1 μM 7-Cyclo for 72 h
(by ELISA). Results were normalized by the total form of protein and indicate mean ± SEM (n = 4). HUAECs-VEGFR2 cells are HUAECs overexpressing VEGFR2.
Statistical analyses between groups were performed by an unpaired t test. (B) VEGFR2 is more highly expressed in embryonic cells (hESC-ECs or mAECs E12.5) than
in postnatal cells (HUAECs or mAECs p1), either in human or mouse cells. Percent of positive cells was calculated based on the isotype controls (gray plot) and is
shown in the histogram plots. Values in histogram plots indicate mean ± SEM (n = 3). (C and D) Effect of 7-Cyclo (0.1 M) and ZM323881 (1 M; VEGFR2-specific
inhibitor) in the phosphorylation of AKT (C) and ERK (D) in hESC-derived ECs and HUAECs for 15 min (by ELISA). Results were normalized by the total form of
protein and indicate mean ± SEM (n = 4). Statistical analyses between experimental group “no-treatment” and the other two groups was performed by one-way
ANOVA test followed by a Newman–Keuls multiple comparisons test. (E) Correlation between the inhibition of VEGFR2 phosphorylation and the inhibition of
AKT (P = 0.914) or ERK (P = 0.987) phosphorylation. Correlations indicate a strong relationship between both events. Values indicate mean ± SEM (n = 4).
(F) Schematic representation of the impact of 7-Cyclo in embryonic ECs. The 7-Cyclo inhibits VEGFR2 phosphorylation, leading to the inhibition of downstream
pathways involved in cell proliferation and survival (ERK and AKT pathways). The 7-Cyclo also increases the expression of the molecules involved in vascular injury
such as ADMA, propeptide vWF, eNOS, ICAM-1, eSelectin, and HO-1. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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slopes of both graphs (Fig. 6E). The correlations found (AKT:
0.914; ERK: 0.987) indicate that there is a strong relationship
between AKT and ERK inhibition and VEGFR2 blocking by
7-Cyclo. Together, our results indicate that 7-Cyclo inhibits the
kinase activity of VEGFR2, which further inhibits AKT and
ERK signaling pathways, inducing cell death (Fig. 6F). The
higher sensitivity of embryonic ECs to 7-Cyclo than postnatal
ECs is likely due to high expression of VEGFR2.
Discussion
In this study, we described a platform for the high-throughput
screening of chemicals that affect embryonic vascular develop-
ment. This platform includes (i) the differentiation of hPSCs into
embryonic-like ECs, followed by their maturation under flow
shear stress; (ii) high-throughput identification of small mole-
cules that interfered with embryonic-like EC survival in a two-
step protocol; (iii) confirmation of the hits in embryonic-like ECs
cultured under flow shear stress; and (iv) final validation in
mouse embryonic ECs and the zebrafish animal model.
Previous studies have performed very useful in vivo screens for
inhibitors of vascular development in zebrafish embryos (36) and
Xenopus embryos (37). Although in vivo screening systems in-
tegrate all physiological processes, they have some limitations that
can be addressed by high-throughput cellular platforms. First, the
identified compounds might affect embryonic as well as fetal/adult
vasculature. In the present work, we identified drugs that more
specifically target embryonic ECs using a two-step protocol in-
volving (i) a primary screen against a nonvascular cell (ligament
cells) and (ii) a primary screen against fetal ECs (HUAECs).
Second, in the in vivo testing, the test compounds did not have
direct access to their target, but were metabolized or resorbed. In
addition, other cell types or the immune system can alter the drug
effects, which makes difficult to attribute the primary target for
the drug (21). Third, studies in animal embryos (zebrafish, Xen-
opus, rats, and rabbits) do not account for differences in the vas-
cular development between humans and small animals (4).
Recent studies have shown the derivation of ECs from hPSCs
with high efficiency in chemical defined medium (38, 39) and
exhibiting features of arterial-like ECs (39–42); however, it was
unclear what their maturation stage was under flow conditions
and whether they exhibited embryonic or adult features. Both
features have significant impact on drug screening, as confirmed
by results of the present work. In this study, we derived
embryonic-like ECs. At the gene level, clustering analyses
showed that hESC-derived ECs were more related to embryonic
than adult ECs. Although a defined set of embryonic EC gene
markers has not yet been identified, in this study, we identified
328 embryonic EC genes, some of which were validated by qRT-
PCR (DLL1, EPHB2, LYN, TEK, ID1, NRP2, CAST, FLT1,
IGF1, DKK3, NIN, LEF1, and SORBS3). We further showed that
embryonic ECs have a high expression of tyrosine kinases, in-
cluding EFS, VEGFR2, LYN, EGFR, ZAP70, NRP1, and TEK.
Importantly, flow shear stress enhanced the maturation of ECs
as shown by an up-regulation of EC mechanosensory complex
proteins VECAD and VEGFR2, cell alignment in the direction
of the flow, and production of HSPGs.
There is currently a limited set of chemical compounds that
have been described to affect human embryonic vascular devel-
opment. Thalidomide, which was prescribed in the 1960s, is the
most well-known embryonic vascular disruptive drug. Thalido-
mide inhibits angiogenesis via the prevention of filopodial ex-
tensions from the endothelial tip cell (43). Thalidomide is one of
the drugs of the LOPAC; however, the drug was not a hit in our
screening. This finding was likely due to the high concentration
of the drug (>5 μM) that is required to affect cell viability, as
previously shown (44).
In the present study, the screening of the chemical library was
performed at one concentration (4.5 μM), and the endpoint was
cell viability after 96 h of exposure. This endpoint may reflect
multiple effects of the selected drug, and thus we further con-
firmed its toxicity in multiple secondary assays for low concen-
trations of the drug (up to 0.001 μM). Although not explored, the
effect of the chemical library in specific properties of ECs, such as
migration, capillary tube formation, vascular inflammation, among
others (24), may also be important for the identification of drugs
affecting embryonic vascular development. The concentration
selected for the screening was based on previous screenings (21,
22, 24) and was below the toxicity of thalidomide (>5 μM) (44).
In recent years, several drugs have been identified to disrupt
vascular development in zebrafish and Xenopus embryos (36, 37,
45); however, in many cases, the drugs have not been validated in
human cells, and most of the drugs likely affect both the adult
vascular system and embryonic vascular development. In this study,
we identified two embryonic EC inhibitors, namely, fluphen-
azine and 7-Cyclo, using high-throughput screening. Fluphenazine
medication is not recommended during pregnancy; however, for a
woman who is taking this medication at the time of conception, by
the time the pregnancy is confirmed, most or all of the organo-
genesis has already occurred. An international epidemiological
survey of drug use in pregnancy showed that 3.5% of the women
took psychotropic drugs during pregnancy (46). It was found that
the human fetus exposed to fluphenazine had severe rhinorrhea,
respiratory distress, and delayed extrapyramidal symptoms (47).
Our study shows that fluphenazine has a higher effect in the dis-
ruption of embryonic vascular networks than postnatal ones.
Previous studies have demonstrated that 7-Cyclo (20 μM) dis-
rupts blood vessel formation in Xenopus embryos and is an inhibitor
of in vitro lymphangiogenesis (21, 37). Our results indicated that
hESC-derived ECs exposed to medium supplemented with 7-Cyclo
(1 μM) for 24 h under flow conditions showed an up-regulation of
inflammatory genes and secretion of vascular injury markers. This
effect was higher on hESC-derived ECs compared with HUAECs.
Similar results were also obtained for mouse embryonic ECs and
postnatal ECs (i.e., mouse embryonic ECs were sensitive to the
toxicity of 7-Cyclo, whereas postnatal ECs showed no measurable
effect against the same compound). We also confirmed in vivo the
effect of 7-Cyclo on ISV development of zebrafish embryos and
showed that it specifically blocked the motility and sprouting be-
havior of arterial ECs.
The effect of 7-Cyclo against embryonic-like ECs involved the
inhibition of VEGFR2, which is highly expressed in embryonic ECs
compared with fetal or adult ECs. This inhibition (at 0.1 μM) occurred
in embryonic ECs (hESC-ECs), but not in fetal ECs (HUAECs), due
to the high level of VEGFR2 expression in the former. However, the
overexpression of VEGFR2 in HUAECs makes these cells sensitive
to 0.1 μM 7-Cyclo. The inhibition of VEGFR2 leads to a significant
inhibition of AKT and ERK pathways with higher efficiency than a
commercial inhibitor. This inhibition, in turn, leads to cell necrosis. In
conclusion, the platform described in this study is promising for the
identification of compounds that affect vascular development, as well
as to study embryonic vascular biology.
Methods
Detailed methods are available in SI Appendix, SI Materials and Methods.
hPSC Culture and Differentiation. Undifferentiated hESCs (passages 33–36; H9,
WiCell) or hiPSCs K2 (passages 32–35; cord blood-derived iPSCs kindly donated
by Ulrich Martin; Leibniz Research Laboratories for Biotechnology and Artifi-
cial Organs, Department of Cardiothoracic, Transplantation and Vascular Sur-
gery, Hannover Medical School, Hannover, Germany) were grown on an
inactivated mouse embryonic fibroblast feeder layer, as described (9, 48). Cells
were induced to differentiate into ECs by using different protocols (SI Ap-
pendix, SI Materials and Methods). hESCs were used with the approval of the
ethics commitee from University of Coimbra.
Isolation of CD31+ Cells. CD31+ cells were isolated from differentiated hESCs
or hiPSCs at day 18 by using MACS (Miltenyi Biotec). Isolated cells were grown
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on Petri dishes (1.5 × 104 cells per cm2) coatedwith 0.1% gelatin and containing
EGM-2 (Lonza) supplemented with SB431542 (10 μM). The methodolo-
gies for cell culture under flow conditions and cell characterization at
gene, protein, and functional levels are provided in SI Appendix, SI Ma-
terials and Methods.
Human and Mouse Primary Cells. HUAECs and HUVECs were acquired from
Lonza. mAECs E12.5 and mAECs p1 were isolated frommice cultured for 2–
3 d in vitro in EC medium and immediately used. The cells were obtained
from Innoprot.
Gene Expression Analyses (Microarray and qRT-PCR), Kinase Activity Quantification,
Phosphorylation of AKT/ERK/VEGFR2, Matrigel Assays, Cell Viability Assays, and
Intracellular Ca2+ Analyses. The methods are found in SI Appendix, SI Materials
and Methods.
Evaluation of the Levels of Vascular Injury by Specific Markers. ELISA kits for
vWF and vWFpp (Gen-Probe GTI Diagnostic) and ADMA (Enzo Life Sciences)
were used to analyze supernatants collected from the shear stress experi-
ments, according to manufacturer’s recommendations.
High-Throughput Screening. The LOPAC (Sigma-Aldrich) was used to screen
compounds that interferewithembryonic ECs. The compoundswere solubilized
in DMSO, and the final concentration used in the screen was 4.5 μM in a final
volume of 200 μL per well (96-well plate). After 4 d of incubation, HUAEC or
hESC-derived EC viability was assessed by using a PrestoBlue (Invitrogen) assay.
Zebrafish Line and Treatment with 7-Cyclo. Zebrafish Tg(fli1a:eGFP)y1 embryos
(30) were used to evaluate the effect of 7-Cyclo on ISV development. The
protocol is described in SI Appendix, SI Materials and Methods.
Statistical Analysis. An unpaired t test or one-way ANOVA with Newman–
Keuls posttest was performed for statistical tests using GraphPad Prism
software. Results were considered significant when P < 0.05.
ACKNOWLEDGMENTS. This work was supported by FEDER through the Pro-
gram COMPETE and by Portuguese funding through FCT in context of the
projects PTDC/SA-BEB/098468/2008, PTDC/SAU-TOX/121887/2010, and MITP-
TB/ECE/0013/2013. The work was also supported by COMPETE in the context
of Project “Stem-Cell Based Platforms for Regenerative and Therapeutic
Medicine” (Centro-07-ST24-FEDER-002008). H.V. was supported by FCT for
BD and BPD Fellowships SFRH/BD/40077/2007 and SFRH/BPD/87039/2012.
1. Makris SL, et al. (2011) Current and future needs for developmental toxicity testing.
Birth Defects Res B Dev Reprod Toxicol 92(5):384–394.
2. Vasvari G, Dyckhoff G, Herold-Mende C (2005) Thalidomide protects endothelial cells
from doxorubicin-induced apoptosis but alters cell morphology—a rebuttal. J Thromb
Haemost 3(4):816–817, author reply 817–818.
3. Knudsen TB, Kleinstreuer NC (2011) Disruption of embryonic vascular development in
predictive toxicology. Birth Defects Res C Embryo Today 93(4):312–323.
4. Kleinstreuer NC, et al. (2011) Environmental impact on vascular development pre-
dicted by high-throughput screening. Environ Health Perspect 119(11):1596–1603.
5. Mellin GW, Katzenstein M (1962) The saga of thalidomide. Neuropathy to embry-
opathy, with case reports of congenital anomalies. N Engl J Med 267:1184–92.
6. Tideman E, Marsál K, Ley D (2007) Cognitive function in young adults following in-
trauterine growth restriction with abnormal fetal aortic blood flow. Ultrasound
Obstet Gynecol 29(6):614–618.
7. Levenberg S, Zoldan J, Basevitch Y, Langer R (2007) Endothelial potential of human
embryonic stem cells. Blood 110(3):806–814.
8. Fiddes LK, et al. (2010) A circular cross-section PDMS microfluidics system for repli-
cation of cardiovascular flow conditions. Biomaterials 31(13):3459–3464.
9. Ferreira LS, et al. (2007) Vascular progenitor cells isolated from human embryonic
stem cells give rise to endothelial and smooth muscle like cells and form vascular
networks in vivo. Circ Res 101(3):286–294.
10. Smart N, et al. (2007) Thymosin beta4 induces adult epicardial progenitor mobiliza-
tion and neovascularization. Nature 445(7124):177–182.
11. James D, et al. (2010) Expansion and maintenance of human embryonic stem cell-
derived endothelial cells by TGFbeta inhibition is Id1 dependent. Nat Biotechnol
28(2):161–166.
12. Haase A, et al. (2009) Generation of induced pluripotent stem cells from human cord
blood. Cell Stem Cell 5(4):434–441.
13. Swiers G, et al. (2013) Early dynamic fate changes in haemogenic endothelium
characterized at the single-cell level. Nat Commun 4:2924.
14. Malek AM, Alper SL, Izumo S (1999) Hemodynamic shear stress and its role in ath-
erosclerosis. JAMA 282(21):2035–2042.
15. Tzima E, et al. (2005) A mechanosensory complex that mediates the endothelial cell
response to fluid shear stress. Nature 437(7057):426–431.
16. Potter DR, Damiano ER (2008) The hydrodynamically relevant endothelial cell glyco-
calyx observed in vivo is absent in vitro. Circ Res 102(7):770–776.
17. Ho PY, Zhong WB, Ho YS, Lee WS (2006) Terbinafine inhibits endothelial cell mi-
gration through suppression of the Rho-mediated pathway. Mol Cancer Ther 5(12):
3130–3138.
18. Ho PY, Liang YC, Ho YS, Chen CT, Lee WS (2004) Inhibition of human vascular en-
dothelial cells proliferation by terbinafine. Int J Cancer 111(1):51–59.
19. Pullamsetti S, et al. (2005) Increased levels and reduced catabolism of asymmetric and
symmetric dimethylarginines in pulmonary hypertension. FASEB J 19(9):1175–1177.
20. Louden C, et al. (2006) Biomarkers and mechanisms of drug-induced vascular injury in
non-rodents. Toxicol Pathol 34(1):19–26.
21. Schulz MMP, et al. (2012) Phenotype-based high-content chemical library screening
identifies statins as inhibitors of in vivo lymphangiogenesis. Proc Natl Acad Sci USA
109(40):E2665–E2674.
22. Kitami T, et al. (2012) A chemical screen probing the relationship between mito-
chondrial content and cell size. PLoS One 7(3):e33755.
23. Qosa H, et al. (2016) High-throughput screening for identification of blood-brain
barrier integrity enhancers: A drug repurposing opportunity to rectify vascular am-
yloid toxicity. J Alzheimers Dis 53(4):1499–1516.
24. Kleinstreuer NC, et al. (2014) Phenotypic screening of the ToxCast chemical library to
classify toxic and therapeutic mechanisms. Nat Biotechnol 32(6):583–591.
25. Ghebes CA, van Lente J, Post JN, Saris DB, Fernandes H (2017) High-throughput
screening assay identifies small molecules capable of modulating the BMP-2 and
TGF-β1 signaling pathway. J Biomol Screen 22(1):40–50.
26. Alves H, Dechering K, Van Blitterswijk C, De Boer J (2011) High-throughput assay for
the identification of compounds regulating osteogenic differentiation of human
mesenchymal stromal cells. PLoS One 6(10):e26678.
27. Laurencin CT, Freeman JW (2005) Ligament tissue engineering: An evolutionary
materials science approach. Biomaterials 26(36):7530–7536.
28. Blanc A, Pandey NR, Srivastava AK (2004) Distinct roles of Ca2+, calmodulin, and
protein kinase C in H2O2-induced activation of ERK1/2, p38 MAPK, and protein kinase
B signaling in vascular smooth muscle cells. Antioxid Redox Signal 6(2):353–366.
29. Borbiev T, et al. (2003) Role of CaM kinase II and ERK activation in thrombin-induced
endothelial cell barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 285(1):
L43–L54.
30. Lawson ND, Weinstein BM (2002) In vivo imaging of embryonic vascular development
using transgenic zebrafish. Dev Biol 248(2):307–318.
31. Bayliss PE, et al. (2006) Chemical modulation of receptor signaling inhibits re-
generative angiogenesis in adult zebrafish. Nat Chem Biol 2(5):265–273.
32. Hirst G, et al. (2006) US Patent 7071199 B1.
33. Arnold LD, et al. (2000) Pyrrolo[2,3-d]pyrimidines containing an extended 5-sub-
stituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett 10(19):
2167–2170.
34. Endo A, Fukuhara S, Masuda M, Ohmori T, Mochizuki N (2003) Selective inhibition of
vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for
VEGFR-2 in human aortic endothelial cell responses to VEGF. J Recept Signal
Transduct Res 23(2-3):239–254.
35. Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat
Med 9(6):669–676.
36. Tran TC, et al. (2007) Automated, quantitative screening assay for antiangiogenic
compounds using transgenic zebrafish. Cancer Res 67(23):11386–11392.
37. Kälin RE, Bänziger-Tobler NE, Detmar M, Brändli AW (2009) An in vivo chemical li-
brary screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis
and lymphangiogenesis. Blood 114(5):1110–1122.
38. Patsch C, et al. (2015) Generation of vascular endothelial and smooth muscle cells
from human pluripotent stem cells. Nat Cell Biol 17(8):994–1003.
39. Orlova VV, et al. (2014) Functionality of endothelial cells and pericytes from human
pluripotent stem cells demonstrated in cultured vascular plexus and zebrafish xeno-
grafts. Arterioscler Thromb Vasc Biol 34(1):177–186.
40. Rufaihah AJ, et al. (2013) Human induced pluripotent stem cell-derived endothelial
cells exhibit functional heterogeneity. Am J Transl Res 5(1):21–35.
41. White MP, et al. (2013) Limited gene expression variation in human embryonic stem cell
and induced pluripotent stem cell-derived endothelial cells. Stem Cells 31(1):92–103.
42. Ditadi A, et al. (2015) Human definitive haemogenic endothelium and arterial vas-
cular endothelium represent distinct lineages. Nat Cell Biol 17(5):580–591.
43. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (2009) Thalidomide
induces limb defects by preventing angiogenic outgrowth during early limb forma-
tion. Proc Natl Acad Sci USA 106(21):8573–8578.
44. Kaushal V, Kaushal GP, Melkaveri SN, Mehta P (2004) Thalidomide protects endo-
thelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb
Haemost 2(2):327–334.
45. Wang C, et al. (2010) Rosuvastatin, identified from a zebrafish chemical genetic
screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur
Urol 58(3):418–426.
46. Marchetti F, Romero M, Bonati M, Tognoni G; Collaborative Group on Drug Use in
Pregnancy (CGDUP) (1993) Use of psychotropic drugs during pregnancy. A report of
the international co-operative drug use in pregnancy (DUP) study. Eur J Clin
Pharmacol 45(6):495–501.
47. Iqbal MM, et al. (2005) The potential risks of commonly prescribed antipsychotics:
during pregnancy and lactation. Psychiatry (Edgmont) 2(8):36–44.
48. Vazão H, das Neves RP, Grãos M, Ferreira L (2011) Towards the maturation and
characterization of smooth muscle cells derived from human embryonic stem cells.
PLoS One 6(3):e17771.
Vazão et al. PNAS | Published online March 27, 2017 | E3031
A
PP
LI
ED
BI
O
LO
G
IC
A
L
SC
IE
N
CE
S
PN
A
S
PL
U
S
